Developer docs
API playgroundTry for free, no card

Search company profiles

Circle Pharma

Full company profile

uuid00004nm

Namestring
Circle Pharma
Legal namestring
Circle Pharma, Inc.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Circle Pharma is a clinical-stage biopharmaceutical company developing orally bioavailable macrocyclic therapeutics designed to disrupt intracellular protein-protein interactions historically considered undruggable by conventional small molecules. Founded around 2013 and headquartered in South San Francisco, California, the company is led by President and CEO David J. Earp, J.D., Ph.D., with co-founders Matthew P. Jacobson, Ph.D. and Scott Lokey pioneering the foundational understanding of synthetic macrocycle cell permeability. The company's proprietary MXMO™ (Macrocycles by Crosslinking MOtif) platform combines computationally driven structure-based design with advanced fully synthetic macrocycle chemistry, AI/ML, and physics-based simulations to screen permeability-biased virtual and physical chemical libraries and synthesize diverse compound variations from natural and unnatural building blocks.

Circle Pharma's pipeline is anchored by CID-078, a first-in-class oral macrocyclic cyclin A/B RxL inhibitor currently in a multicenter Phase 1 clinical trial (NCT06577987) enrolling patients with advanced solid tumors harboring RB1 alterations. A second program, CID-165, an oral first-in-class cyclin D1 RxL inhibitor, was nominated as a development candidate in December 2025 with IND submission expected in late 2026, targeting cyclin D1-driven cancers including ER-positive breast cancer and lymphomas. An additional undisclosed cyclin program is partnered with Boehringer Ingelheim in a deal valued at up to $607 million. The primary patient populations served are oncology patients with tumors characterized by RB1 loss, elevated E2F activity, or cyclin overexpression, including small cell lung cancer, ovarian cancer, and hormone receptor-positive breast cancer.

The company is pre-revenue and operates an enterprise field-sales and partnership model, monetizing through future product commercialization and pharma collaborations. Strategic channels include presentations at major investor conferences (J.P. Morgan Healthcare Conference, Oppenheimer, TD Cowen, Leerink) and scientific conferences (AACR, AACR-NCI-EORTC). Circle Pharma is backed by a deep investor syndicate including The Column Group (lead investor), Nextech Invest, Pfizer, Eli Lilly, Euclidean Capital, Pandect, Pavilion Capital, Hartford HealthCare Endowment, Lifeforce Capital, Hongsen Investment, and Berkeley Catalyst Fund. The company employed approximately 60 staff as of May 2025 and expanded its South San Francisco facilities that year.

Short descriptiontext

Circle Pharma is a clinical-stage biopharmaceutical company using its proprietary MXMO™ macrocycle platform to develop orally bioavailable therapeutics against undruggable cyclin targets in oncology. Its lead program CID-078 is in Phase 1 for advanced solid tumors, with CID-165 in preclinical development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
macrocyclic peptide therapeutics, oncology drug development, protein-protein interaction inhibitors, cell cycle therapeutics, biopharmaceutical pipeline
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Macrocyclic Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Circle Pharma is pre-revenue. The company is developing macrocyclic therapeutics for cancer with lead program CID-078 in Phase 1 clinical trials. Revenue will be generated through future product sales upon regulatory approval.

circlepharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Circle Pharma is a clinical-stage biopharmaceutical company developing orally bioavailable macrocyclic peptide therapeutics that target intracellular protein-protein interactions for cancer treatment. Its pipeline includes CID-078 (cyclin A/B RxL inhibitor in Phase 1), CID-165 (cyclin D1 RxL inhibitor development candidate), and an undisclosed cyclin program partnered with Boehringer Ingelheim, all enabled by its proprietary MXMO discovery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Single-agent tumor regressions demonstrated in multiple xenograft preclinical models with CID-078
+1 more record
Product overview1 text field

Circle Pharma is a clinical-stage biopharmaceutical company developing targeted macrocycle therapeutics for cancer using its proprietary MXMO™ platform. The company's pipeline includes CID-078 (cyclin A/B RxL inhibitor in Phase 1 clinical trials), CID-165 (cyclin D1 RxL inhibitor as development candidate), and an undisclosed cyclin program partnered with Boehringer Ingelheim. The MXMO platform enables creation of cell-permeable and orally bioavailable macrocycles against historically undruggable targets.

Product and service4 records
1MXMO Platform
CategoryDrug Discovery Platform
Description

Proprietary drug discovery platform that combines computationally driven structure-based design, AI/ML and physics-based simulation with advanced synthetic macrocycle chemistry to create intrinsically cell-permeable and orally bioavailable macrocycle therapeutics targeting historically undruggable intracellular protein-protein interactions. Used internally to generate Circle's pipeline candidates.

2CID-078
CategoryInvestigational Oncology Therapeutic
Description

First-in-class oral macrocyclic cyclin A/B RxL inhibitor currently in Phase 1 clinical development for patients with advanced solid tumors harboring RB1 alterations. Selectively targets tumor cells with oncogenic alterations causing cell cycle dysregulation, including small cell lung cancer and ovarian cancer.

3CID-165
CategoryInvestigational Oncology Therapeutic
Description

First-in-class oral macrocyclic cyclin D1 RxL inhibitor nominated as development candidate for Circle's second oncology program. Targets cyclin D1-driven cancers including ER-positive breast cancer and lymphomas. IND submission expected late 2026.

4Undisclosed Cyclin Program (Boehringer Ingelheim partnership)
CategoryInvestigational Oncology Therapeutic (Partnered)
Description

Discovery-stage cyclin program partnered with Boehringer Ingelheim targeting multiple tumor types under a partnership deal valued at up to $607 million. Specific cyclin target is undisclosed.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-09
Description

Circle Pharma partnered with Eli Lilly to use the TuneLab AI/ML platform for developing cancer therapies. TuneLab provides access to drug discovery models trained on over $1 billion of Lilly's research data. The platform uses federated computing technology to protect proprietary data while enabling collaborative AI model training.

2Boehringer Ingelheim
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Circle Pharma entered into a partnership valued at up to $607 million with Boehringer Ingelheim for a preclinical cyclin program (undisclosed cyclin target). Boehringer Ingelheim sees potential in Circle Pharma's first-in-class cancer approach targeting cyclins.

circlepharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops constrained bicyclic peptides (Bicycles) as targeted therapeutics for oncology, including BT8009 for nectin-4 and BT5528 for EphA2. The constrained peptide modality targeting tumor-specific antigens is the closest analog to Circle's macrocyclic peptide approach.

TypeDirect peer
Description

Develops tri-complex inhibitors that disrupt protein-protein interactions in oncology, including RMC-6236 (daraxonrasib) targeting RAS(ON) multi-complex PPIs. Circle board director Stephen Kelsey serves as RVMD's president and CMO, providing direct organizational linkage and conceptual alignment.

TypeDirect peer
Description

Pioneers targeted protein degradation via PROTACs to address historically undruggable protein targets in oncology, with vepdegestrant (ARV-471) in Phase 3 for breast cancer. Shares Circle's focus on disrupting previously challenging cancer-driving proteins through novel chemistry.

TypeDirect peer
Description

Uses motion-based computational drug design platform to develop precision oncology therapeutics, including RLY-4008 (lirafugratinib) for FGFR2. Co-founded by Matthew Jacobson, who is also Circle Pharma's co-founder, creating direct technology and organizational lineage.

TypeDirect peer
Description

Develops precision oncology therapeutics using synthetic lethality approaches, including TNG462 for PRMT5 and TNG260 for synthetic lethality targets. Shares Circle's focus on identifying and exploiting specific cancer-driving vulnerabilities through novel mechanism of action.

TypeDirect peer
Description

Develops cancer therapeutics targeting chromatin regulatory proteins and transcriptional machinery, including FHD-286 for AML and mutant SMARCA4 programs. Addresses complex protein-protein interactions in oncology, conceptually adjacent to Circle's cyclin RxL approach.

TypeBroad incumbent
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel drug targets and therapeutics. Circle's SVP of Research Marie Evangelista was previously VP of Oncology at Recursion, providing organizational and methodological overlap with Circle's MXMO AI/ML design approach.

TypeBroad incumbent
Description

Computational drug design platform serving pharma clients and developing an internal pipeline. Their physics-based simulation platform has direct conceptual overlap with Circle's MXMO approach of using computational and physics-based modeling to design drug-like macrocycles.

TypeEmerging player
Description

Develops targeted protein degraders using heterobifunctional small molecules, including KT-474 for immunology and KT-413 for MYC-driven lymphomas. Pursues 'undruggable' cancer targets through novel chemistry, conceptually adjacent to Circle's macrocycle approach to PPI disruption.

TypeEmerging player
Description

Precision oncology company targeting the RAS/MAPK pathway with multiple programs including naporafenib (pan-RAF inhibitor) and ERAS-007 (ERK1/2 inhibitor). Competes for similar oncology patient populations using novel small molecule approaches against historically difficult cancer targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Circle Pharma

Oncology Macrocyclic Therapeuticscirclepharma.com

Circle Pharma is a clinical-stage biopharmaceutical company using its proprietary MXMO™ macrocycle platform to develop orally bioavailable therapeutics against undruggable cyclin targets in oncology. Its lead program CID-078 is in Phase 1 for advanced solid tumors, with CID-165 in preclinical development.

What Circle Pharma does

Circle Pharma is a clinical-stage biopharmaceutical company developing orally bioavailable macrocyclic therapeutics designed to disrupt intracellular protein-protein interactions historically considered undruggable by conventional small molecules. Founded around 2013 and headquartered in South San Francisco, California, the company is led by President and CEO David J. Earp, J.D., Ph.D., with co-founders Matthew P. Jacobson, Ph.D. and Scott Lokey pioneering the foundational understanding of synthetic macrocycle cell permeability. The company's proprietary MXMO™ (Macrocycles by Crosslinking MOtif) platform combines computationally driven structure-based design with advanced fully synthetic macrocycle chemistry, AI/ML, and physics-based simulations to screen permeability-biased virtual and physical chemical libraries and synthesize diverse compound variations from natural and unnatural building blocks.

Circle Pharma's pipeline is anchored by CID-078, a first-in-class oral macrocyclic cyclin A/B RxL inhibitor currently in a multicenter Phase 1 clinical trial (NCT06577987) enrolling patients with advanced solid tumors harboring RB1 alterations. A second program, CID-165, an oral first-in-class cyclin D1 RxL inhibitor, was nominated as a development candidate in December 2025 with IND submission expected in late 2026, targeting cyclin D1-driven cancers including ER-positive breast cancer and lymphomas. An additional undisclosed cyclin program is partnered with Boehringer Ingelheim in a deal valued at up to $607 million. The primary patient populations served are oncology patients with tumors characterized by RB1 loss, elevated E2F activity, or cyclin overexpression, including small cell lung cancer, ovarian cancer, and hormone receptor-positive breast cancer.

The company is pre-revenue and operates an enterprise field-sales and partnership model, monetizing through future product commercialization and pharma collaborations. Strategic channels include presentations at major investor conferences (J.P. Morgan Healthcare Conference, Oppenheimer, TD Cowen, Leerink) and scientific conferences (AACR, AACR-NCI-EORTC). Circle Pharma is backed by a deep investor syndicate including The Column Group (lead investor), Nextech Invest, Pfizer, Eli Lilly, Euclidean Capital, Pandect, Pavilion Capital, Hartford HealthCare Endowment, Lifeforce Capital, Hongsen Investment, and Berkeley Catalyst Fund. The company employed approximately 60 staff as of May 2025 and expanded its South San Francisco facilities that year.

Circle Pharma firmographics

Firmographics
Name
Circle Pharma
Legal name
Circle Pharma, Inc.
Website
https://circlepharma.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Circle Pharma is a clinical-stage biopharmaceutical company using its proprietary MXMO™ macrocycle platform to develop orally bioavailable therapeutics against undruggable cyclin targets in oncology. Its lead program CID-078 is in Phase 1 for advanced solid tumors, with CID-165 in preclinical development.
Ownership category
akta.pro rank

Circle Pharma industry classification

Industry
Product category
Oncology Macrocyclic Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Macrocyclic peptide therapeutics
  • Oncology drug development
  • Protein-protein interaction inhibitors
  • Cell cycle therapeutics
  • Biopharmaceutical pipeline

Where Circle Pharma is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Circle Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Circle Pharma is pre-revenue. The company is developing macrocyclic therapeutics for cancer with lead program CID-078 in Phase 1 clinical trials. Revenue will be generated through future product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Circle Pharma product offering

Product offering

Core offering

Circle Pharma is a clinical-stage biopharmaceutical company developing orally bioavailable macrocyclic peptide therapeutics that target intracellular protein-protein interactions for cancer treatment. Its pipeline includes CID-078 (cyclin A/B RxL inhibitor in Phase 1), CID-165 (cyclin D1 RxL inhibitor development candidate), and an undisclosed cyclin program partnered with Boehringer Ingelheim, all enabled by its proprietary MXMO discovery platform.

Product overview

Circle Pharma is a clinical-stage biopharmaceutical company developing targeted macrocycle therapeutics for cancer using its proprietary MXMO™ platform. The company's pipeline includes CID-078 (cyclin A/B RxL inhibitor in Phase 1 clinical trials), CID-165 (cyclin D1 RxL inhibitor as development candidate), and an undisclosed cyclin program partnered with Boehringer Ingelheim. The MXMO platform enables creation of cell-permeable and orally bioavailable macrocycles against historically undruggable targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • MXMO Platform Proprietary drug discovery platform that combines computationally driven structure-based design, AI/ML and physics-based simulation with advanced synthetic macrocycle chemistry to create intrinsically cell-permeable and orally bioavailable macrocycle therapeutics targeting historically undruggable intracellular protein-protein interactions. Used internally to generate Circle's pipeline candidates.
  • CID-078 First-in-class oral macrocyclic cyclin A/B RxL inhibitor currently in Phase 1 clinical development for patients with advanced solid tumors harboring RB1 alterations. Selectively targets tumor cells with oncogenic alterations causing cell cycle dysregulation, including small cell lung cancer and ovarian cancer.
  • CID-165 First-in-class oral macrocyclic cyclin D1 RxL inhibitor nominated as development candidate for Circle's second oncology program. Targets cyclin D1-driven cancers including ER-positive breast cancer and lymphomas. IND submission expected late 2026.
  • Undisclosed Cyclin Program (Boehringer Ingelheim partnership) Discovery-stage cyclin program partnered with Boehringer Ingelheim targeting multiple tumor types under a partnership deal valued at up to $607 million. Specific cyclin target is undisclosed.

Quantifiable outcome

  • Single-agent tumor regressions demonstrated in multiple xenograft preclinical models with CID-078
  • +1 more outcomes

Companies that use Circle Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Circle Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Circle Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • Eli LillycoreTechnology or Integration · 9 September 2025Circle Pharma partnered with Eli Lilly to use the TuneLab AI/ML platform for developing cancer therapies. TuneLab provides access to drug discovery models trained on over $1 billion of Lilly's research data. The platform uses federated computing technology to protect proprietary data while enabling collaborative AI model training.
  • Boehringer IngelheimflagshipStrategic or Co-development Partner · 1 January 2024Circle Pharma entered into a partnership valued at up to $607 million with Boehringer Ingelheim for a preclinical cyclin program (undisclosed cyclin target). Boehringer Ingelheim sees potential in Circle Pharma's first-in-class cancer approach targeting cyclins.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Circle Pharma competitors and assessment

Company assessment

Direct peers

  • Bicycle Therapeutics: Develops constrained bicyclic peptides (Bicycles) as targeted therapeutics for oncology, including BT8009 for nectin-4 and BT5528 for EphA2. The constrained peptide modality targeting tumor-specific antigens is the closest analog to Circle's macrocyclic peptide approach.
  • Revolution Medicines: Develops tri-complex inhibitors that disrupt protein-protein interactions in oncology, including RMC-6236 (daraxonrasib) targeting RAS(ON) multi-complex PPIs. Circle board director Stephen Kelsey serves as RVMD's president and CMO, providing direct organizational linkage and conceptual alignment.
  • Arvinas: Pioneers targeted protein degradation via PROTACs to address historically undruggable protein targets in oncology, with vepdegestrant (ARV-471) in Phase 3 for breast cancer. Shares Circle's focus on disrupting previously challenging cancer-driving proteins through novel chemistry.
  • Relay Therapeutics: Uses motion-based computational drug design platform to develop precision oncology therapeutics, including RLY-4008 (lirafugratinib) for FGFR2. Co-founded by Matthew Jacobson, who is also Circle Pharma's co-founder, creating direct technology and organizational lineage.
  • Tango Therapeutics: Develops precision oncology therapeutics using synthetic lethality approaches, including TNG462 for PRMT5 and TNG260 for synthetic lethality targets. Shares Circle's focus on identifying and exploiting specific cancer-driving vulnerabilities through novel mechanism of action.
  • Foghorn Therapeutics: Develops cancer therapeutics targeting chromatin regulatory proteins and transcriptional machinery, including FHD-286 for AML and mutant SMARCA4 programs. Addresses complex protein-protein interactions in oncology, conceptually adjacent to Circle's cyclin RxL approach.

Broad incumbents

  • Recursion: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel drug targets and therapeutics. Circle's SVP of Research Marie Evangelista was previously VP of Oncology at Recursion, providing organizational and methodological overlap with Circle's MXMO AI/ML design approach.
  • Schrodinger: Computational drug design platform serving pharma clients and developing an internal pipeline. Their physics-based simulation platform has direct conceptual overlap with Circle's MXMO approach of using computational and physics-based modeling to design drug-like macrocycles.

Emerging players

  • Kymera Therapeutics: Develops targeted protein degraders using heterobifunctional small molecules, including KT-474 for immunology and KT-413 for MYC-driven lymphomas. Pursues 'undruggable' cancer targets through novel chemistry, conceptually adjacent to Circle's macrocycle approach to PPI disruption.
  • Erasca: Precision oncology company targeting the RAS/MAPK pathway with multiple programs including naporafenib (pan-RAF inhibitor) and ERAS-007 (ERK1/2 inhibitor). Competes for similar oncology patient populations using novel small molecule approaches against historically difficult cancer targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Circle Pharma social profiles

Digital presence

Circle Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Circle Pharma leadership team

Management profile

Number of profiles

Profiles21 records

Circle Pharma funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Circle Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Circle Pharma

What does Circle Pharma do?

Circle Pharma is a clinical-stage biopharmaceutical company developing orally bioavailable macrocyclic peptide therapeutics that target intracellular protein-protein interactions for cancer treatment. Its pipeline includes CID-078 (cyclin A/B RxL inhibitor in Phase 1), CID-165 (cyclin D1 RxL inhibitor development candidate), and an undisclosed cyclin program partnered with Boehringer Ingelheim, all enabled by its proprietary MXMO discovery platform.

Is Circle Pharma a public or private company?

Circle Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Circle Pharma founded?

Circle Pharma was founded in 2013. It employs 51 to 100 people.

Where is Circle Pharma based?

Circle Pharma is headquartered in South San Francisco, United States, in the North America region.

How does Circle Pharma make money?

One revenue line is on record: drug Development and Commercialization.

Who are Circle Pharma's main competitors?

Direct peers on record are Bicycle Therapeutics, Revolution Medicines, Arvinas, Relay Therapeutics, Tango Therapeutics and Foghorn Therapeutics. Broad incumbents are Recursion and Schrodinger. Emerging players are Kymera Therapeutics and Erasca.

Does Circle Pharma have an API?

No public API is recorded for Circle Pharma.

What industry is Circle Pharma in?

Circle Pharma's product category is Oncology Macrocyclic Therapeutics. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterCircle Pharma strengthens leadership teamCircle Pharma promoted Marie Evangelista to chief scientific officer and appointed Mary Ellen Sillivos as senior vice president and head of human resources. The appointments strengthen the company's leadership team as it advances its pipeline of next-generation targeted macrocycle therapeutics and prepares for its next stage of growth.Business Wire BlogCircle Pharma Strengthens Leadership Team with Promotion of Marie Evangelista, Ph.D., to Chief Scientific Officer and Addition of Mary Ellen Sillivos as SVP and Head of Human ResourcesCircle Pharma promoted Marie Evangelista to chief scientific officer and appointed Mary Ellen Sillivos as senior vice president and head of human resources. The appointments strengthen leadership as the company advances its pipeline of next-generation targeted macrocycle therapeutics for cancer.pharmaphorumWhich biotechs have raised new VC financing this week?Sling Therapeutics raised $123 million for a phase 3 trial of its oral IGF-1R inhibitor linsitinib for thyroid eye disease, Circle Pharma closed a $92.5 million round for its CID-165 breast cancer drug, and RegCell raised $66 million for Treg therapy trials. Sling's ORBIT trial is expected to enroll about 130 patients, while Circle plans to start human trials in Q1 2027.Pulse 2.0Circle Pharma Raises $92.5 Million Series E To Advance Cyclin D1 Cancer Drug CID-165 Into Clinical DevelopmentCircle Pharma raised $92.5 million in a Series E round led by The Column Group to advance CID-165, its cyclin D1 inhibitor, into clinical development for ER-positive breast cancer. The company expects the first-in-class drug to enter clinical trials in the first quarter of 2027, with funding supporting early clinical programs and its broader cyclin-targeted pipeline.The Pharma LetterCircle Pharma raises $92.5 million to advance cyclin D1 inhibitor toward clinicCircle Pharma raised $92.5 million in Series E financing to advance CID-165, a cyclin D1 inhibitor, into clinical development for ER-positive breast cancer. The round was led by The Column Group with participation from Nextech Invest, RA Capital, Euclidean Capital, and a strategic investment from Eli Lilly.MarketScreenerCircle Pharma, Inc. announced that it has received $92.5 million in funding from Eli Lilly and Company, Euclidean Capital LLC, RA Capital Management, L.P., The Column Group, LLC, Nextech Invest Ltd.Circle Pharma, Inc. announced a $92.5 million funding round led by The Column Group on September 16, 2026. The round included participation from Eli Lilly, Euclidean Capital, Nextech Invest, and new investor RA Capital Management, with shares issued as convertible preferred shares.BioSpaceCircle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical DevelopmentCircle Pharma announced an oversubscribed $92.5 million Series E financing led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, a first-in-class cyclin D1 inhibitor, into clinical development for ER+ breast cancer in Q1 2027.Business Wire BlogCircle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical DevelopmentCircle Pharma announced an oversubscribed $92.5 million Series E financing led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, a first-in-class cyclin D1 inhibitor, into clinical development for ER+ breast cancer in Q1 2027.CirclepharmaCircle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical DevelopmentCircle Pharma announced an oversubscribed $92.5 million Series E financing led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, a first-in-class cyclin D1 inhibitor, into clinical development for ER+ breast cancer in Q1 2027.Venture Capital Access OnlineCircle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical DevelopmentCircle Pharma announced an oversubscribed $92.5 million Series E financing led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The funds will advance CID-165, a first-in-class cyclin D1 inhibitor, into clinical development for ER+ breast cancer in Q1 2027.